SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is a major talking point as investors eagerly await its business update call, expecting Dr. PSS to reveal breakthroughs in Anktiva's global strategy and the BioShield platform, while simultaneously navigating intense community chatter around perceived short interest manipulation.

Indonesia Energy Corp. Ltd. operates as an oil and gas, exploration, and production company. It engages in oil and gas assets portfolio with a mix between medium-sized producing blocks and exploration blocks with significant resources. Its portfolio includes Kruh, Citarum, and Rangkas Area. The company was founded by James J. Huang and Wirawan Jusuf in 2014 and is headquartered in Jakarta, Indonesia.

Indonesia Energy Corp Ltd

Indonesia Energy Corp Ltd (INDO) is trending amidst intense community debate following a steep sell-off, with many questioning potential dilution and market manipulation as the stock paradoxically plummets despite surging crude oil prices and escalating Middle East tensions driving other small-cap energy plays higher.

CrowdStrike Holdings, Inc. provides cybersecurity products and services to stop breaches. It offers cloud-delivered protection across endpoints, cloud workloads, identity and data, and threat intelligence, managed security services, IT operations management, threat hunting, Zero Trust identity protection, and log management. CrowdStrike serves customers worldwide. The company was founded by George P. Kurtz, Gregg Marston, and Dmitri Alperovitch on November 7, 2011 and is headquartered in Austin, TX.

Crowdstrike Holdings Inc - Ordinary Shares - Class A

Crowdstrike Holdings Inc

Crowdstrike is trending after delivering a double beat on earnings with solid guidance, reinforcing its position as a cybersecurity leader amidst increasing global cyber threats. The community is actively discussing whether AI is a tailwind or a threat to the sector, with many viewing recent dips as a buying opportunity given the crucial and growing demand for advanced security solutions.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin (WEEDCOIN CRYPTO) is seeing strong community interest and positive momentum, largely driven by enthusiasm for the approaching 4/20 cannabis culture event. Investors are discussing its potential as a "culture coin" on the Solana blockchain, citing its consistent development and unique position within the expanding cannabis ecosystem.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna is surging amid a flurry of positive developments, including a significant settlement in its patent dispute with Arbutus Biopharma and Genevant, the FDA's reversal to review its seasonal flu vaccine, and a European recommendation for its COVID-19/flu combination shot, driving strong community optimism for its pipeline and a potential short squeeze.

GitLab, Inc. engages in the intelligent DevSecOps platform for software innovation. The firm enables organizations to increase developer productivity, improve operational efficiency, reduce security and compliance risk, and accelerate digital transformation. The company was founded by Dmitriy Zaporozhets and Sid Sijbrandij in 2011 and is headquartered in San Francisco, CA.

Gitlab Inc - Ordinary Shares - Class A

Gitlab Inc

Gitlab is trending as investors react to its latest financial report, which, despite beating recent revenue and EPS figures, presented weaker-than-anticipated forward guidance, sparking a polarized discussion about its growth trajectory and high stock-based compensation amid broader software sector concerns and persistent buyout speculation.

Kraken Robotics, Inc. engages in the design, manufacture, and sale of software-centric sensors, subsea batteries, thrusters and underwater robotic systems. It operates through the following geographical segments: Asia Pacific, Europe, Middle East and Africa, North America, and Other. The company was founded on May 14, 2008, and is headquartered in Mt. Pearl, Canada.

Kraken Robotics Inc

Kraken Robotics is trending following its strategic acquisition of Covelya Group, a "company-maker" deal that significantly expands its subsea technology offerings and market reach as a global prime contractor. The community is discussing the long-term bullish implications of this vertical integration and significant battery orders, alongside short-term concerns regarding share dilution.

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.

Rigel Pharmaceuticals

Rigel Pharmaceuticals is trending due to preliminary Q4 financial results surpassing expectations, confirming profitability and strong product sales growth. This, alongside promising clinical data for its pipeline assets and an active biotech M&A landscape, fuels widespread community speculation about the company's significant undervaluation and potential for a strategic acquisition, despite persistent short interest.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizer is trending as investors weigh its recent earnings beat and a new cancer drug approval against a subdued 2026 outlook. Community discussions are heavily focused on concerns about the efficacy and tolerability of its acquired obesity pipeline, particularly when compared to existing market leaders.

Ross Stores, Inc. engages in the operation of off-price retail apparel and home accessories stores. Its products include branded and designer apparel, accessories, footwear, and home fashions through the Dress for Less and dd's DISCOUNTS brands. The company was founded by Stuart G. Moldaw in 1957 and is headquartered in Dublin, CA.

Ross Stores, Inc.

Ross Stores is trending after reporting a significant Q4 earnings beat and robust Q1 sales outlook, fueled by strong customer response and operational improvements, though community conversation remains divided on whether the future guidance justifies its current valuation amidst a value-seeking consumer environment.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The test uses the company’s digital platform with GRAIL’s advanced cancer screening technology.</li><li>The multi-cancer early detection test identifies cancers signals that currently lack recommended screening methods.</li><li>The company is expected to report its fourth-quarter and full-year 2025 results on February 23.</li></ul>Hims &amp; Hers Health, Inc. (HIMS) came under the spotlight on Wednesday after the company unveiled a blood test to detect signals for more than 50 types of cancer, often before symptoms appear.Called the Hims &amp; Hers Multi-Cancer Test by Galleri, the test uses the company’s digital platform with GRAIL’s advanced cancer screening technology. The multi-cancer early detection test identifies shared cancer signals, including those for cancers that currently lack recommended screening methods.“GRAIL believes making validated MCED tests available as a complement to recommended cancer screenings can help to increase cancer detection before cancers spread, improve outcomes, and enable this breakthrough technology to be available to more people,” said&nbsp; Josh Ofman, President at GRAIL.<a href="https://stocktwits.com/symbol/HIMS">HIMS</a> was among the top trending tickers on Stocktwits while the shares edged 1% lower after the opening bell.<h2 class="st-heading-2">Stocktwits Users Reaction</h2>Despite the intraday drop, retail sentiment on Stocktwits turned 'bullish' from 'neutral' a day earlier, amid 'high' message volumes.<img src="https://news.stocktwits-cdn.com/HIMS_jpg_766ade307d.webp" alt="HIMS.jpg">One user said the news could become a big growth catalyst for the company.<stembedurl>https://stocktwits.com/TheBullishTrade/message/643934180</stembedurl>Another user said "preventative healthcare is the future."<stembedurl>https://stocktwits.com/TheBullishTrade/message/643934180</stembedurl>The stock has been under selling pressure lately, slumping more than 25% so far this year.Hims &amp; Hers Health is expected to report its fourth-quarter (Q4) and full-year 2025 financial results on February 23. During its Q3 report, the company had guided FY2025 revenue between $2.335 billion and $2.355 billion and adjusted earnings guidance between $307 million and $317 million.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-bsx-stock-falling-today/cZbS6QuR4Z8">BSX Stock Tumbles Pre-Market On Softer 2026 Sales Growth Forecast</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a smartphone displays the logo of Hims & Hers Health in front of a screen showing the company's stock market chart. (Photo illustration by Cheng Xin/Getty Images)

HIMS Stock Garners Retail Buzz After Launching New Multi-Cancer Detection Test

The company unveiled a blood test to detect signals for more than 50 types of cancer.

HIMY
Defiance Leveraged Long Income HIMS ETF

Feed

News

Sentiment

Fundamentals

Info

Latest HIMY News

HIMYDefiance Leveraged Long Income HIMS ETF